1515 Holocombe Blvd
Houston, TX 77030
United States
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
BRCA1, BRCA2, ovarian cancer, prevention
pembrolizumab, combination chemotherapy, ovarian cancer, immunotherapy, tumor immune microenvironment, translational, clinical trial, feasibility
immune checkpoint inhibitor, AXL inhibitor, Batiraxcept, platinum-resistant ovarian cancer